Myoglobinuria in two patients with Duchenne muscular dystrophy after treatment with zoledronate: a case-report and call for caution.

Détails

Cette publication est une ancienne version. Cette notice est remplacée par serval:BIB_7FF72A5306B3
Ressource 1 Sous embargo indéterminé.
Accès restreint UNIL
Etat: Public
Version: Final published version
Licence: Tous droits réservés
ID Serval
serval:BIB_2EAAEFF3D2E3
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Institution
Titre
Myoglobinuria in two patients with Duchenne muscular dystrophy after treatment with zoledronate: a case-report and call for caution.
Périodique
Neuromuscular disorders
Auteur⸱e⸱s
Ivanyuk A., García Segarra N., Buclin T., Klein A., Jacquier D., Newman C.J., Bloetzer C.
ISSN
1873-2364 (Electronic)
ISSN-L
0960-8966
Statut éditorial
Publié
Date de publication
10/2018
Peer-reviewed
Oui
Volume
28
Numéro
10
Pages
865-867
Langue
anglais
Notes
Publication types: Case Reports ; Journal Article
Publication Status: ppublish
Résumé
Rhabdomyolysis with myoglobinuria is a recognized complication of dystrophinopathies. It can be triggered by infections, exercise or volatile anesthetics. To our knowledge, it has never been reported in boys with Duchenne muscular dystrophy (DMD) after the administration of bisphosphonates. We report two patients with DMD who presented an apparent transient rhabdomyolysis with myoglobinuria after zoledronate administration. Possible mechanisms could involve hypophosphatemia, a known dose-dependent side effect of bisphosphonates, and/or direct myotoxicity of biphosphonates. Physicians and families should be aware of rhabdomyolysis with myoglobinuria as a potential uncommon side effect of bisphosphonates in DMD, in particular of zoledronate.
Mots-clé
Adolescent, Bone Density Conservation Agents/adverse effects, Bone Density Conservation Agents/therapeutic use, Humans, Male, Muscular Dystrophy, Duchenne/complications, Muscular Dystrophy, Duchenne/drug therapy, Myoglobinuria/etiology, Zoledronic Acid/adverse effects, Zoledronic Acid/therapeutic use, Duchenne muscular dystrophy, bisphosphonates, myoglobinuria, zoledronate
Pubmed
Web of science
Création de la notice
10/03/2020 16:22
Dernière modification de la notice
30/10/2023 8:52
Données d'usage